Nanox Expands U.S. Southeast Footprint with New Distribution Agreement
Petach Tikva, Israel – Nano-X Imaging Ltd. (NASDAQ: NNOX) announced today a strategic partnership with Imperial Imaging Technology LLC, a Georgia-based provider of diagnostic imaging solutions, to broaden access to its Nanox.ARC system across the southeastern United States. The collaboration, formalized on March 3, 2026, will focus on deploying the Nanox.ARC, a novel digital tomosynthesis system, in Georgia, Alabama, Tennessee, North Carolina, South Carolina, and Northern Florida. This expansion aims to provide more clinical settings with affordable 3D imaging capabilities, utilizing a lower radiation dose compared to traditional CT scans.
The agreement signifies a key step in Nanox’s commercial rollout strategy within the U.S. Market, particularly targeting the orthopedic segment. Nanox Impact Inc., the company’s U.S.-based subsidiary, finalized the distribution agreement with Imperial Imaging Technology, leveraging the latter’s established network and expertise in the region. The Nanox.ARC system utilizes a multi-source digital tomosynthesis approach, offering a potentially cost-effective alternative to conventional computed tomography (CT) imaging. This technology is designed to make 3D imaging more accessible, addressing a critical demand in healthcare facilities and orthopedic practices.
Nanox.ARC: A New Approach to Medical Imaging
The Nanox.ARC system represents a departure from traditional CT technology. It employs a digital tomosynthesis approach, which uses multiple low-dose X-ray images taken from different angles to create a 3D representation of the anatomy. According to the press release, this method reduces radiation exposure compared to traditional CT scans while still providing detailed 3D images. The system is designed to be more affordable and easier to deploy, potentially expanding access to advanced imaging in a wider range of clinical settings.
The Nanox.ARC is reimbursable under an existing Current Procedural Terminology (CPT) code, and does not require pre-authorization, streamlining the process for healthcare providers and patients. StockTitan reports this feature as a significant advantage for adoption. This accessibility is particularly relevant for orthopedic practices, where 3D imaging is crucial for diagnosis and treatment planning.
Imperial Imaging Technology: A Regional Partner
Imperial Imaging Technology LLC, founded in 2019, will play a pivotal role in the distribution and support of the Nanox.ARC system within the designated six-state territory. The company will be responsible for all marketing and sales efforts, as well as providing ongoing customer support. As detailed by StockTitan, Imperial will too coordinate product demonstrations and facilitate clinical evaluations for orthopedic practices and healthcare facilities, fostering adoption and integration of the Nanox.ARC system.
Based in Georgia, Imperial Imaging Technology brings regional expertise and a strong network within the orthopedic and musculoskeletal healthcare communities. This local knowledge will be instrumental in effectively reaching potential customers and providing tailored support. The company’s focus on customer service and clinical evaluation will be key to demonstrating the value and benefits of the Nanox.ARC system to healthcare professionals.
Nanox’s Channel Partner Strategy
This distribution agreement with Imperial Imaging Technology is part of a broader strategy by Nanox to build a geographically diverse network of regional distributors across the United States. The company is actively expanding its channel partner program to accelerate the commercial rollout of the Nanox.ARC system and increase its market reach. This approach allows Nanox to leverage the local expertise and established relationships of its distribution partners, facilitating faster and more effective market penetration.
Nanox’s commitment to innovation in medical imaging technology is reflected in its development of the Nanox.ARC system. The company aims to address the limitations of traditional CT imaging by offering a more affordable, accessible, and lower-radiation alternative. The partnership with Imperial Imaging Technology represents a significant step towards realizing this vision and bringing advanced imaging capabilities to a wider range of healthcare providers and patients in the U.S. Southeast.
Financial Context and Market Reaction
As of March 3, 2026, Nano-X Imaging Ltd. (NNOX) experienced a slight decrease in stock price, falling 0.81%. Yahoo Finance reports the stock was trading at approximately $2.46, with a volume of 647,037 shares. This volume is below the 20-day average of 1,122,779, suggesting a muted initial market response to the news. The company’s 52-week high stands at $6.42, while the 52-week low is $2.11. Nanox’s market capitalization pre-news was $154,957,454.
Despite the modest initial market reaction, the long-term implications of this distribution agreement could be significant for Nanox. Successful deployment of the Nanox.ARC system in the U.S. Southeast could drive revenue growth and enhance the company’s position in the medical imaging market. The focus on the orthopedic segment, combined with the system’s affordability and reduced radiation dose, positions Nanox to capture a growing share of this significant market.
Key Takeaways:
- Nanox has partnered with Imperial Imaging Technology to distribute the Nanox.ARC system across six southeastern U.S. States.
- The Nanox.ARC offers a potentially more affordable and lower-radiation alternative to traditional CT scans.
- Imperial Imaging Technology will handle all marketing, sales, and customer support within the designated territory.
- This agreement is part of Nanox’s broader strategy to expand its U.S. Market presence through regional distribution partners.
The next key development to watch will be the initial deployment and clinical evaluations of the Nanox.ARC system in the target states, with results expected to be reported throughout the remainder of 2026. We encourage readers to share their thoughts on this development and its potential impact on the future of medical imaging in the comments below.